About & Mission
The prevention of blindness and the early detection and treatment of multiple systemic and ocular diseases.
What we offer
RetinalGeniX is an ophthalmic research and development company focused on developing High-Resolution Retinal Imaging and Pharmaco-Genetic Mapping™ technologies intended to prevent blindness through the early detection and treatment of ocular diseases and also to detect initial physiological changes that could indicate possible future systemic disease including neurodegenerative, cardiovascular, vascular, metabolic, and diabetic conditions.
Chronic Systemic Diseases
The World Health Organization said that the increasing toll of Non-Communicable Diseases meant that if the trend were to continue, by around 2050, chronic diseases such as cardiovascular diseases, cancer, diabetes and respiratory illnesses – will account for 86 per cent of the 90 million deaths each year: a staggering 90 per cent increase in absolute numbers, since 2019.
Our Progress
-
2024
NASDAQ Uplisting planned for 2025
Phase II clinical trials -
2023
Patent granted for Patient Home Monitoring and Physician Alert System for Ocular Anatomy
Filed 2 preliminary patents for drugs RGT 2023 and RGT 2024Added Interim CFO Virender Ahluwalia
CRO hired AvaniaAdded Fred Chasalow Ph.D. therapeutic drug selection and development
Added Herbert Gould, MD to oversee contact lens development
Added Dessy Boneva MD, FACS to Board of Directors
Institutional Review Board process approved
-
2022
Listed on the OTCQB marketAdded Vinay Mehindru, MD, MBA to board of directors
Acquired DNA/GPS Inc
Added Dr. Perich to medical advisory board
-
2021
Obtained license agreement for retinal technologiesFiled S-1 (OTC:RTGN)
-
2020
Doubled ophthalmic engineering team -
2019
Opened HQ and lab6 ophthalmic medical advisors added
Contract manufacturing agreement (ADM Tronics)
Added ophthalmic engineering team
-
2017
3 Patent Awards for Visualization of Eye Anatomy4 Trademarks for RetinalGeniX Including DNA/GPS, RNA/GPS